storta mancanza di respiro Fitness prostate cancer clinical trials working group gelato credere Germoglio

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial | Nature Medicine

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer | NEJM

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology - European Urology

PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar

Managing Castrate- Resistant Metastatic Prostate Cancer Elisabeth I. Heath, MD Associate Professor of Medicine and Oncology Wayne State University/Karmanos. - ppt download

Prostate cancer clinical states model; framework for patient management... | Download Scientific Diagram

Criteria of Progression for Trial Eligibility By Disease Manifestation | Download Table

Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Journal of Clinical Oncology

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors | Prostate Cancer and Prostatic Diseases

ESMO 2021: Apalutamide Efficacy and Safety in Asian Patients with Metastatic Castration-Sensitive Prostate Cancer

The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration | Journal of Clinical Oncology

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study - The Lancet Oncology

Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art | Radiology

The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Journal of Clinical Oncology

Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz

AUA 2020: Apalutamide for Metastatic Castration-Sensitive Prostate Cancer in TITAN: Prognostic Importance of Prostate-Specific Antigen Responses

Table of Contents page: Clinical Genitourinary Cancer

Advanced Prostate Cancer: Treatment Advances and Future Directions: Trends in Cancer

Second-line Hormonal Therapy for the Management of Metastatic Castration-resistant Prostate Cancer: a Real-World Data Study Using a Claims Database | Scientific Reports

The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer - European Urology Focus

Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open ...